Mitral valve replacement is one of the most common heart valve surgeries in China. In recent years, with the increase in degenerative valve diseases, older patients, and the progress of anti-calcification technology of biological valves, the proportion of mitral valve biological valve replacement has been increasing year by year. After the damage of traditional mitral valve biological valves, re-operation of valve replacement with thoracotomy is required. However, the adhesion between the heart and sternum, as well as the damage caused by cardiopulmonary bypass and cardiac arrest, can cause significant trauma to elderly patients and those with multiple organ dysfunction, leading to increased mortality and complication rates. In recent years, interventional valve surgery, especially transcatheter valve-in-valve surgery, has developed rapidly. This procedure can correct the damaged mitral valve function without stopping the heart, but there are still many differences between its technical process and conventional aortic valve replacement surgery. Therefore, organizing and writing multicenter expert recommendations on the technical process of transcatheter valve-in-valve surgery for damaged mitral valve biological valves is of great significance for the training and promotion of this technology.
Citation: ZHANG Haibo, PAN Xiangbin, GUO Yingqiang, WEI Lai, YANG Jian, ZHOU Daxin, WU Yongjian, MENG Xu, LIU Liming, Chinese Research Hospital Association (CRHA) Heart Valve Disease Professional Committee, Asian Association for Heart Valve Disease (AAHVD) China Chapter. Multicenter expert recommendations on interventional valve-in-valve technology for mitral bioprosthetic valve destruction in China. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(8): 1090-1095. doi: 10.7507/1007-4848.202406009 Copy
Copyright © the editorial department of Chinese Journal of Clinical Thoracic and Cardiovascular Surgery of West China Medical Publisher. All rights reserved
-
Previous Article
Chinese thoracic surgery expert consensus on rational diagnosis and treatment of pulmonary nodules with a diameter≤2 cm (2024) -
Next Article
Mid to long-term clinical outcomes improvement through dual antiplatelet therapy after coronary artery bypass grafting: Interpretation of DACAB-FE trial